Representative Image 
National

Biocon starts clinical study to evaluate efficacy of itolozumab

The development also underpins the company's commitment to bring innovative, affordable medicines, that address unmet patient needs, to market expeditiously, he added

PTI

NEW DELHI: Biotechnology major Biocon on Wednesday said it has initiated a clinical study in collaboration with Equillium Inc to evaluate efficacy of Itolizumab in patients with Ulcerative Colitis.

Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialised in handling UC cases, it added.

The first patient who intended to participate in the study was screened on December 1, 2022, the company said.

''The commencement of the Phase two clinical study, that will determine its efficacy for the treatment of Ulcerative Colitis, is an important step forward in our efforts to bring its benefit to patients in India suffering from this disease,'' Biocon Managing Director and CEO Siddharth Mittal said.

The development also underpins the company's commitment to bring innovative, affordable medicines, that address unmet patient needs, to market expeditiously, he added.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Deepathoon row: SC permits lamp lighting atop Thiruparankundram hill on Nov 24 as one-time measure

Former DMK Minister Moorthy denies involvement in illegal quarrying

How can Parandur airport project be dropped midway after land acquisition, asks Madras HC

SC dismisses TN's pleas for direction to Karnataka on release of additional water from Cauvery river

Raids on ex-minister Moorthy aimed at diverting attention from drug busts: DMK chief Stalin

SCROLL FOR NEXT